close× Call Us 1(844) 401-0111

What is the Biogen 251AD201 Alzheimer’s disease study?

This is a voluntary research study to evaluate the effects of an investigational medication on Alzheimer’s disease (AD). People who are interested in participating will be screened for probable AD or mild cognitive impairment to see if they qualify. The study will last approximately 2 years. Participants are monitored for safety and cognitive function throughout the trial. Biogen Inc. is sponsoring this research study.

What is the purpose of the Biogen 251AD201 Alzheimer’s disease study?

The purpose of this study is to evaluate the safety and tolerability of the investigational drug, BIIB092, in eligible participants with prodromal to mild AD. Participants will be randomly assigned (like flipping a coin) to receive either BIIB092 or a placebo to compare their effects on AD. A placebo is an inactive substance that looks like BIIB092, but has no effect. The investigational drug will be administered intravenously (in your vein) at various time points during the study. BIIB092 has previously been studied in cognitively normal adults; however, this is the first study in an AD population.

Eligibility

This is a voluntary research study for people ages 50-80 years old. Everyone undergoes the Informed Consent process, during which time people can agree to participate in the study or not. Those who agree to participate in this study will undergo testing and evaluation by the study doctor for probable AD or mild cognitive impairment to see if they qualify for the study. All qualified participants must have a study partner with whom they spend regular time and would be able to support them through the duration of the study.

To learn more about the Biogen 251AD201 Alzheimer’s disease study, please call (401) 455-6402 or send an e-mail to memory@butler.org. Ask about the “Biogen 251AD201 Alzheimer’s Trial.”

View more information on other current research studies at Butler Hospital.

Subscribe to our monthly Memory Matters
e-newsletter.

Subscribe